
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Future of Pharma Manufacturing
over 13 years ago
Standards-Setting Activities on Impuritiesover 13 years ago
A Look Ahead at Manufacturing and Regulationover 13 years ago
The Transformation to Process-Centered Organizationover 13 years ago
The Latest in IT/Automation/Process controlover 13 years ago
A Look Ahead for 2013over 13 years ago
Pharma Conversation & Communityover 13 years ago
Strategies in API Scale Upover 13 years ago
Report from Brazil January 2013over 13 years ago
Offshoring Biomanufacturing





